Sign In

Jay Mazelsky

President and CEO at IDEXX

Jay Mazelsky is the President and Chief Executive Officer of IDEXX Laboratories, Inc., a leading technology company in the field of pet healthcare and diagnostics. He has held this position since October 2019, having previously served as Interim CEO from June to October 2019. Before his current role, he was the Executive Vice President responsible for various segments, including the North American Companion Animal Group and several innovation initiatives at IDEXX from August 2012 to June 2019.13

Career Background::

  • IDEXX Laboratories (2012 - Present):

    • Executive Vice President (August 2012 - October 2019)
    • Interim President and CEO (June 2019 - October 2019)
    • President and CEO (October 2019 - Present)
  • Philips Healthcare (2010 - 2012):

    • Senior Vice President and General Manager of Computed Tomography, Nuclear Medicine, and Radiation Therapy Planning.
  • Agilent Technologies (1997 - 2002):

    • General Manager of the Medical Consumables Business Unit and Executive in Charge of integrating Agilent’s Healthcare Group into Philips.
  • Hewlett-Packard (1988 - 1996):

    • Held various roles in finance, marketing, and business planning.

Education::

  • Bachelor’s degree in Mathematics from the University of Rochester.
  • Master of Business Administration (MBA) from the University of Chicago Booth School of Business.13

In addition to his role at IDEXX, Mazelsky serves on the board of directors for Dentsply Sirona, Inc. since May 2023. His leadership at IDEXX has been marked by a focus on innovation in veterinary diagnostics and services for both companion animals and livestock.12

Highlights

Jun 4 · linkedin

Today, I’m proud to announce the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. This marks the tenth menu addition launched for the Catalyst platform since 2012, clearly demonstrating IDEXX’s Technology for Life strategy–our commitment to extending the clinical value and diagnostic capabilities of our technologies over time.

Pancreatitis is a common disease among cats and dogs. While treatable, it can prove fatal if not identified early. Now, with the Catalyst Pancreatic Lipase Test, veterinarians can receive quantitative results in under ten minutes. By delivering quantitative diagnostic insights during the patient visit, the new test empowers veterinarians to confidently confirm or rule out pancreatitis and immediately begin treatment, saving crucial time and improving patient outcomes.

Learn more by visiting our press release for full details.

Apr 30 · linkedin

In January of this year, IDEXX announced the planned expansion of our Fecal Dx® Antigen Testing solution to include detection of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. I’m proud to share that this week, IDEXX Reference Laboratories customers in North America began receiving Cystoisospora results with their Fecal Dx antigen testing panels, at no additional cost. This marks the second expansion of the Fecal Dx antigen platform in less than two years and reinforces our commitment to continuous innovation.

The Companion Animal Parasite Council (CAPC) recommends fecal testing for puppies and kittens four times in their first year and twice annual testing for adult pets. The addition of Fecal Dx antigen testing detects up to five times more infections than flotation tests alone by identifying parasite-specific antigens rather than relying on the presence of eggs. With its industry-leading antigen detection capabilities, Fecal Dx antigen testing identifies infections earlier than other testing modalities, enabling veterinarians to develop targeted treatment and prevention plans with confidence. Fecal Dx antigen testing also offers the additional benefit of providing a more streamlined workflow, ultimately redeploying staff time back to patient and client care. Freeing up staff time is especially important when 87% of veterinary practices are looking to increase their operational efficiency.

Learn more about our complete Fecal Dx testing offering, including peer-reviewed studies, clinical reference guides, and support for talking to pet owners about the importance of parasite screening on our updated Fecal Dx resource page.

#VeterinaryMedicine

Related Questions

What are Jay Mazelsky's key achievements since becoming CEO of IDEXX?
How did Jay Mazelsky's background at Philips Healthcare prepare him for his role at IDEXX?
What strategies has Jay Mazelsky implemented at IDEXX during his tenure?
How did Jay Mazelsky's experience at Agilent Technologies influence his leadership style at IDEXX?
What challenges has Jay Mazelsky faced as CEO of IDEXX, and how has he addressed them?
Jay Mazelsky
Jay Mazelsky, photo 1
Jay Mazelsky, photo 2
Add to my network

Location

Portland, Maine Area